Brokers Issue Forecasts for Blueprint Medicines Co.’s FY2026 Earnings (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) – Equities researchers at SVB Leerink dropped their FY2026 earnings per share (EPS) estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Thursday, April 28th. SVB Leerink analyst A. Berens now expects that the biotechnology company will earn $1.00 per share for the year, down from their prior forecast of $1.03. SVB Leerink has a “Market Perform” rating and a $82.00 price objective on the stock.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last released its quarterly earnings data on Wednesday, February 16th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.28). The business had revenue of $107.00 million during the quarter, compared to analyst estimates of $104.14 million. Blueprint Medicines had a negative net margin of 357.66% and a negative return on equity of 31.04%. The firm’s revenue was up 213.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.53) EPS.

A number of other analysts also recently commented on BPMC. Zacks Investment Research upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating and set a $68.00 price objective for the company in a report on Monday, March 28th. HC Wainwright cut their price target on shares of Blueprint Medicines from $135.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, February 17th. StockNews.com initiated coverage on shares of Blueprint Medicines in a report on Thursday, March 31st. They set a “sell” rating for the company. Morgan Stanley cut their price target on shares of Blueprint Medicines from $111.00 to $92.00 and set an “equal weight” rating for the company in a report on Tuesday, February 1st. Finally, JMP Securities restated a “buy” rating and set a $152.00 price target on shares of Blueprint Medicines in a report on Monday, April 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Blueprint Medicines presently has an average rating of “Buy” and a consensus target price of $106.45.

BPMC stock opened at $60.23 on Friday. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -5.49 and a beta of 0.95. Blueprint Medicines has a 12 month low of $53.26 and a 12 month high of $117.86. The firm has a 50-day moving average of $63.55 and a two-hundred day moving average of $84.21.

Hedge funds have recently modified their holdings of the business. CWM LLC purchased a new position in Blueprint Medicines in the 4th quarter valued at approximately $34,000. Exane Derivatives lifted its position in shares of Blueprint Medicines by 45.8% during the 1st quarter. Exane Derivatives now owns 567 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 178 shares during the last quarter. Covestor Ltd purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth $46,000. Rockefeller Capital Management L.P. lifted its position in shares of Blueprint Medicines by 3,253.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 503 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 488 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of Blueprint Medicines by 51.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 661 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 225 shares during the last quarter.

In other Blueprint Medicines news, Director Mark Alan Goldberg purchased 5,000 shares of the firm’s stock in a transaction on Thursday, March 3rd. The stock was bought at an average price of $59.98 per share, with a total value of $299,900.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 761 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $60.27, for a total transaction of $45,865.47. The disclosure for this sale can be found here. Insiders have sold a total of 10,575 shares of company stock valued at $677,614 in the last ninety days. 3.34% of the stock is currently owned by corporate insiders.

Blueprint Medicines Company Profile (Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Further Reading

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.